



# Licensing opportunity

## New inhibitors for treating of symptoms of Alzheimer's disease and other dementias

### Field of use

Alzheimer's disease and other dementias

### Current state of technology

Laboratory tested, preclinical

### Patent status

Patent pending

### Publication

*Scientific Reports* 2016, 6, 39495

### Developed by

University of Ljubljana, Faculty of Pharmacy and Institut de Biologie Structurale

### Reference

UL20150787007


### Contact details

Urša Jerše,

Phone: +386 2418528

E-mail:

intelektualna.lastnina@uni-lj.si



### Background

Alzheimer's disease (AD) is a progressive neurodegenerative disorder of central nervous system. According to »World Alzheimer disease 2015«, 46.8 million people worldwide are living with dementia in 2015. This number will almost double every 20 years. The global costs of dementia have increased from US\$ 604 billion in 2010 to US\$ 818 billion in 2015, an increase of 35.4%.

### Description of the Invention

The invention relates to novel inhibitors of butyrylcholinesterase which increase the concentration of neurotransmitter acetylcholine in the patients with AD and thereby improve their cognitive functions and memory.

### Main Advantages

Inhibitors of butyrylcholinesterase are capable to alleviate the symptoms also in late stages of Alzheimer's disease when currently available drugs are no longer active.